Literature DB >> 31526609

Graft Choice for Anterior Cruciate Ligament Reconstruction With a Concomitant Non-surgically Treated Medial Collateral Ligament Injury Does Not Influence the Risk of Revision.

Eleonor Svantesson1, Eric Hamrin Senorski2, Matilda Östergaard3, Alberto Grassi4, Ferid Krupic5, Olof Westin6, Kristian Samuelsson6.   

Abstract

PURPOSE: To compare the risk of anterior cruciate ligament (ACL) revision and the patient-reported outcome after ACL reconstruction with a concomitant non-surgically treated medial collateral ligament (MCL) injury with regard to 3 ACL graft choices; the use of semitendinosus (ST), the use of semitendinosus-gracilis (ST-G), and the use of patellar tendon (PT) autograft. It was hypothesized that the use of ST-G would be associated with a greater risk of ACL revision and poorer patient-reported knee function.
METHODS: Patients older than 15 years of age registered for a primary ACL reconstruction with a concomitant non-surgically treated MCL injury in the Swedish National Knee Ligament Registry were assessed for eligibility. Three groups were created according to ACL autograft choice; the ST, the ST-G, and the PT group. The primary outcomes were ACL revision and the 1- and 2-year Knee injury and Osteoarthritis Outcome Score (KOOS), including the KOOS patient acceptable symptom state (PASS). Cox regression analysis was applied to determine the proportional hazard ratio (HR) of primary ACL reconstruction survival. The KOOS was compared using the Mann-Whitney U test and Fisher exact test.
RESULTS: A total of 622 patients (mean age 29.7 years, 42.4% women) were included. There was no difference in the risk of ACL revision for either the ST group (HR 1.354; 95% confidence interval [CI] 0.678-2.702 or the PT group (HR 0.837; 95% CI 0.334-2.100), compared with the ST-G group. The ST group reported a greater mean 2-year KOOS sports and recreation (68.5, standard deviation [SD] 28.5) than the ST-G group (57.4 [SD 27.6], P = .010) and the PT group (54.1 [SD 30.3], P = .006). The ST group was superior in terms of achieving PASS in sports and recreation (55.3%; 95% CI 44.1-66.1%) compared with both the ST-G (37.4%; 95% CI 29.8-45.5%; P = .014) and the PT group (33.9%; 95% CI 22.1-47.4%; P = .009).
CONCLUSIONS: The risk of ACL revision did not differ between HT and PT autografts in patients undergoing ACL reconstruction with a non-surgically treated MCL injury. However, the use of ST-G was associated with poorer 2-year patient-reported knee function compared with the ST. LEVEL OF EVIDENCE: Retrospective comparative trial, Level III.
Copyright © 2019 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31526609     DOI: 10.1016/j.arthro.2019.07.015

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  4 in total

1.  Surgeon's experience, sports participation and a concomitant MCL injury increase the use of patellar and quadriceps tendon grafts in primary ACL reconstruction: a nationwide registry study of 39,964 surgeries.

Authors:  Dzan Rizvanovic; Markus Waldén; Magnus Forssblad; Anders Stålman
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-07-27       Impact factor: 4.114

Review 2.  The management of combined ACL and MCL injuries: A systematic review.

Authors:  Raunak Rao; Rahul Bhattacharyya; Barry Andrews; Rajat Varma; Alvin Chen
Journal:  J Orthop       Date:  2022-08-04

Review 3.  Medial soft-tissue complex of the knee: Current concepts, controversies, and future directions of the forgotten unit.

Authors:  Francisco Requicha; Andrew Comley
Journal:  Orthop Rev (Pavia)       Date:  2021-06-04

4.  Hamstring autograft versus patellar tendon autograft for anterior cruciate ligament reconstruction, which graft has a higher contralateral anterior cruciate ligament injury rate?: A meta-analysis of 5561 patients following the PRISMA guidelines.

Authors:  Peng Zhou; Jun-Cai Liu; Xiang-Tian Deng; Zhong Li
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.